I knew the teams at Winch Capital at a time when my group was developing in 6 countries and mainly in France. I especially remember the support they provided for negotiating acquisitions abroad. The adventure carried on at a steady pace: today, 10 years later, we are active in over 100 countries through 65 offices and the funds of Winch Capital still have a stake in Exclusive Group.

The team enabled me to increase my equity interest and to accelerate the internationalisation of WFCI via external growth transactions. They have provided unfailing support over the past 9 years, supporting the group’s development through its various stages.

When Sanifit decided to establish a US subsidiary, we leveraged BioDiscovery’s substantial US networks and the real world experiences of their European portfolio companies operating in the US.

The involvement of the team from Cabestan Capital has been a major factor in our recent development: in 2 years we have increased our revenue by 12% via internal growth and completed an external growth transaction that doubled the size of the group. We now occupy a strong position in a global market of hi-tech niches. The support of Cabestan Capital has been a key factor in our achievements.

In the ActoMezz team we have found a partner able to provide the support we required for a structural external growth transaction in the aeronautics maintenance field via the acquisition of Latécoère Services, enabling the group to supplement its expertise to serve the aeronautics industry.

In 2013, Winch Capital enabled us to successfully acquire our company, previously part of the Reed Elsevier group. The spin-off was possible thanks to their confidence and conviction in the management team’s development plan. Four years later, the group has accelerated its development via external growth and has sold multiple non-strategic activities, becoming a major player in business intelligence.

The experience provided by Cabestan Capital in the process of our becoming independent was a decisive factor in this phase of our development. We have subsequently seen a remarkable level of organic and external growth and our operational performance has improved significantly.

I have much appreciated the close collaboration with BioDiscovery over these years which has helped our company to develop from a MerckSerono spinout to an international phase 3 biotechnology company.

I have known the teams from Winch Capital since 2008 as the CEO of one of their investments. A few years later they called me back about The Reefer Group: I was won over by the project and now here I am on the front line to take up the challenge!

The organisational expertise of Cabestan was of undeniable added value in the redesign of our finance department. Their high standards in terms of new reporting processes and the transformation of our accounting structures led to significant changes in our organisation and supplier relationships.

I am grateful for the strong support of BioDiscovery in the transformation of Chase from a small virtual company, to a professional biopharmaceutical company with the means to register a drug.

In our world, much more than elsewhere, the digital revolution has transformed our processes. In the face of this challenge, Altavia has significantly augmented its expertise over recent years, notably via 5 digital acquisitions with the support of Winch Capital. We have also appointed a Chief Digital Officer to pursue the development of our digital strategy.

With the arrival of the giant UBER we were forced to transform our business model. We were able to navigate this passage to the new economy with the support of the Cabestan Capital team, notably via the acquisition of the VTC 5S application.

We have been able to bridge the constraints of the buyer and seller thanks to the flexibility and responsiveness shown by the team via an original financing scenario that is profitable for all our shareholders.

BioDiscovery has been a key investor for Genkyotex over the years. The fund lead two rounds of financing and played an instrumental role into Genkyotex’s transformation from a private to a public company. For management, to work with a fund that has experience with M&A, private and public financing is of tremendous strategic value.

We are lucky to have the support of the Cabestan team during the managerial transition our Group is currently undergoing. Their input notably facilitates the emergence of the new top management and the gradual evolution of our management culture.

In Endosense, we had to make some difficult strategic choices and focus on significant operational improvement before holding a competitive and desirable product in our hand. This then resulted in the acquisition of the company at a high valuation. BioDiscovery provided great support to us as a lead investor in keeping the investors and board aligned and orchestrating several bridge financings to overcome this difficult period.